文献速递乳腺癌

口服选择性雌激素受体降解剂治疗ER阳性、HER2阴性转移性乳腺癌的疗效:ESR1野生型与突变亚组的分层分析

WITHDRAWN: Efficacy of Oral SERDs in the treatment of ER+, HER2 - metastatic breast cancer, a stratified analysis of the ESR1 wild type and mutant subgroups.
PubMed 文献 · Ann Oncol · 2023-10-21

该个体患者数据Meta分析纳入ACELERA、AMEERA-3、EMERALD和SERENA-2四项随机对照试验共1290例患者,比较口服SERD与医生选择内分泌治疗。总体人群PFS获益(HR 0.783),ESR1突变亚组获益明显(HR 0.557),而ESR1野生型亚组无显著PFS获益(HR 0.944)。

要点

  • 口服SERD在总体人群较医生选择治疗改善PFS(HR 0.783,95%CI 0.681-0.900,p<0.001)。
  • ESR1突变亚组口服SERD较医生选择治疗显著改善PFS(HR 0.557,95%CI 0.440-0.705,p<0.001)。
  • ESR1野生型亚组口服SERD较医生选择治疗无显著PFS获益(HR 0.944,95%CI 0.783-1.138,p=0.543)。

核心结论

  • 该个体患者数据Meta分析提示总体人群的PFS获益主要由ESR1突变亚组驱动。

研究设计与样本

  • 系统检索Embase、PubMed和Cochrane数据库(从建库至2023年1月21日),纳入报告总体和ESR1突变人群PFS的Kaplan-Meier曲线的口服SERD对比内分泌治疗ER阳性、HER2阴性晚期乳腺癌的随机对照试验。
  • 纳入ACELERA、AMEERA-3、EMERALD和SERENA-2四项随机对照试验,共1290例患者。
  • 应用图形重建算法从报告的Kaplan-Meier曲线估计总体和ESR1突变队列的生存结局,采用KMSubtraction双部匹配算法推导未报告的ESR1野生型亚组的生存数据,并按ESR1突变状态进行个体患者数据Meta分析。

主要发现

  • 总体队列汇总分析中,口服SERD对比医生选择治疗观察到PFS获益(HR 0.783,95%CI 0.681-0.900,p<0.001)。
  • ESR1突变亚组中,口服SERD对比医生选择治疗显示PFS改善(HR 0.557,95%CI 0.440-0.705,p<0.001)。
  • ESR1野生型亚组中,口服SERD对比医生选择治疗未显示显著PFS获益(HR 0.944,95%CI 0.783-1.138,p=0.543)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Oral SERDs are a novel drug class that have been developed to counteract resistance due to ESR1 mutations. Several SERDs have emerged from phase 2 and 3 trials, with the FDA limiting approval for Elacestrant to patients with ESR1mt tumours despite PFS benefit in the overall population. However, questions remain on whether patients with ESR1wt tumours stand to benefit from oral SERDs. PATIENTS AND METHODS: Manuscripts and conference presentations of Randomised Controlled Trials were extracted after a systematic search of Embase, PubMed and Cochrane from inception until January 21,2023. RCTs investigating the efficacy of oral SERDs versus endocrine therapy for ER positive, HER2 negative advanced breast cancer, and which reported the Kaplan Meier (KM) curves of PFS in the overall and ESR1 mutant (ESR1mt) population were selected. A graphical reconstructive algorithm was applied to estimate time-to-event outcomes from reported KM curves in all overall and ESR1mt cohorts. A bipartite matching algorithm, KMSubtraction, was used to derive survival data for unreported (ESR1wt) subgroups. An individual patient data (IPD) meta-analysis was then pursued, pooling data by ESR1 mutation status in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) and Cochrane Guidelines for IPD. RESULTS: The randomized clinical trials ACELERA, AMEERA-3, EMERALD and SERENA-2 were included, totalling 1290 patients. In the pooled analysis of the overall cohort, PFS benefit was observed with oral SERDs when compared with treatment of physicians choice (TPC) (HR 0.783, 95%CI 0.681-0.900, p<0.001). In the ESR1mt subgroup, oral SERDs demonstrated improved PFS (HR 0.557, 95%CI 0.440-0.705, p<0.001) compared to TPC. In the ESR1wt subgroup, oral SERDs demonstrated no significant PFS benefit (HR 0.944, 95%CI 0.783-1.138, p=0.543) when compared to TPC. CONCLUSIONS: The results of this IPD meta-analysis suggests that PFS benefit in the overall population is mainly driven by the ESR1mt subgroup.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Wong NZH, Yap DWT, Ong RJM, et al. WITHDRAWN: Efficacy of Oral SERDs in the treatment of ER+, HER2 - metastatic breast cancer, a stratified analysis of the ESR1 wild type and mutant subgroups. Ann Oncol. 2023. PMID: 37871699. doi:10.1016/j.annonc.2023.10.122

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。